Cell & Gene Therapy — Daily News

One cell & gene therapy story a day, fact-checked, expert curated and explained in plain language.

Allogene's Off-the-Shelf CAR T Improved Skin Scores in 8 of 10 Scleroderma Patients, Some Given No Chemotherapy ALLO-329 8 OF 10 BETTER November 10, 2026 · Clinical Data Allogene's Off-the-Shelf CAR T Improved Skin Scores in 8 of 10 Scleroderma Patients, Some Given No Chemotherapy Allogene reported early Phase 1 data for ALLO-329: 8 of 10 skin-predominant scleroderma patients improved skin scores by 5 or more points, including patients dosed without lymphodepletion. Capricor HOPE-3 cardiac data for Deramiocel in DMD: key LVEF secondary missed (p=0.09) ahead of the 22 November PDUFA date KEY LVEF MISSED SUBGROUP NOMINAL November 10, 2026 · Clinical Data Capricor HOPE-3 cardiac data for Deramiocel in DMD: key LVEF secondary missed (p=0.09) ahead of the 22 November PDUFA date Capricor's HOPE-3 trial of Deramiocel in DMD met its primary endpoint of upper limb function, but the key LVEF secondary missed (p=0.09). Subgroup and LGE findings are nominal. PDUFA is 22 November. Bovine AAV as a lung-directed vector: mouse tropism, AAV9-like production and intermediate human neutralization BOVINE AAV: LUNG INTERMEDIATE NABS November 9, 2026 · Platform / Vector Selection Bovine AAV as a lung-directed vector: mouse tropism, AAV9-like production and intermediate human neutralization A Molecular Therapy Advances paper, published online 5 October 2026, reports bovine AAV lung transduction in mice, AAV9-comparable production and intermediate human serum neutralization. Preclinical only. VeonGen VG801 for Stargardt disease: FDA alignment on Phase 3 design and use of the existing clinical batch FDA ALIGNS ON P3 EXISTING BATCH November 6, 2026 · Clinical Development VeonGen VG801 for Stargardt disease: FDA alignment on Phase 3 design and use of the existing clinical batch VeonGen reports FDA alignment on the VG801 Phase 3 design and on using the existing clinical batch in the pivotal study. Phase 1/2 observations do not establish pivotal efficacy. FDA final Potency Assurance guidance for cell and gene therapies replaces the 2011 potency testing guidance POTENCY RESET 2011 GUIDANCE REPLACED November 3, 2026 · Regulatory Submissions FDA final Potency Assurance guidance for cell and gene therapies replaces the 2011 potency testing guidance FDA's final Potency Assurance guidance for cell and gene therapies replaces the 2011 potency testing guidance and runs from IND through post-market verification. Atsena ATSN-301 for Usher 1B: dual AAV MYO7A data and a six-month GLP toxicology NOAEL in non-human primates DUAL AAV, IND NEXT 6-MONTH GLP NOAEL November 2, 2026 · Preclinical Data Atsena ATSN-301 for Usher 1B: dual AAV MYO7A data and a six-month GLP toxicology NOAEL in non-human primates Atsena reports full-length MYO7A in primate retina from dual AAV plus AAV.SPR and a six-month GLP toxicology NOAEL at the highest dose tested. IND planned for 2027. AviadoBio AVB-406: 84% tau protein lowering in mice at six months, GLP toxicology still ongoing 84% TAU DROP, MICE GLP TOX ONGOING October 30, 2026 · Preclinical Data AviadoBio AVB-406: 84% tau protein lowering in mice at six months, GLP toxicology still ongoing AviadoBio reports 84% tau protein lowering at six months in mice from one IV dose of AVB-406. GLP toxicology is ongoing and first-in-human is planned for 2027. FDA Draft Guidance Could Let Gene Editing Sponsors Add Variants Without New Trials. Only Some Qualify GENE EDITING DRAFT ONLY SOME QUALIFY October 29, 2026 · Regulatory Submissions FDA Draft Guidance Could Let Gene Editing Sponsors Add Variants Without New Trials. Only Some Qualify FDA's October 2026 draft guidance would treat a new gene editing variant inside an established feature space as a manufacturing change. It applies only to monogenic diseases with known variants and one shared editing outcome. FDA Pilot Will Review First-in-Human INDs Piece by Piece. Applications Close October 30 FDA IND PILOT APPLY BY OCT 30 October 23, 2026 · Regulatory Submissions FDA Pilot Will Review First-in-Human INDs Piece by Piece. Applications Close October 30 FDA's Expedited IND Pilot offers rolling review of first-in-human IND components for 8 to 10 sponsor and research institution pairs. Applications close at 11:59pm ET on October 30, 2026. Life Biosciences Reports ER-100 Was Well Tolerated in 3 Glaucoma Patients. The Vision Signal Is Harder to Read FIRST HUMAN DATA October 9, 2026 · Clinical Development Life Biosciences Reports ER-100 Was Well Tolerated in 3 Glaucoma Patients. The Vision Signal Is Harder to Read Life Biosciences reported no serious adverse events in the first 3 glaucoma participants given ER-100, an AAV2-delivered OSK reprogramming therapy, while calling an early visual field signal in 2 of 3 preliminary. After a Patient Death and a Dose Cut, Rocket Needs 7 of 12 Danon Patients to Hit Both Endpoints 7 OF 12 MUST RESPOND October 9, 2026 · Clinical Trial Design & Safety After a Patient Death and a Dose Cut, Rocket Needs 7 of 12 Danon Patients to Hit Both Endpoints Rocket Pharmaceuticals set out the pivotal Phase 2 design for RP-A501 in Danon disease on October 6, 2026. At least 7 of 12 males at a recalibrated, lower dose must meet two response criteria at 12 months. Catalent's Princeton Site Is Set to Become an IRO Center of Excellence, Putting Closed Automation Inside a CDMO CATALENT PRINCETON IRO CENTER OF EXCELLENCE October 8, 2026 · Manufacturing & Business Partnerships Catalent's Princeton Site Is Set to Become an IRO Center of Excellence, Putting Closed Automation Inside a CDMO Ori Biotech says Catalent has joined its Preferred Partner Network, with Princeton, New Jersey set to become an IRO Center of Excellence for autologous process development and GMP manufacturing. The release names no clients, go-live date or capacity. Biohub, DOE, NIH and Partners Commit $1.8 Billion to Open Biology Data for AI. No Therapeutic Modality Is Named $1.8B OPEN DATA NO MODALITY NAMED October 8, 2026 · AI & Data Infrastructure Biohub, DOE, NIH and Partners Commit $1.8 Billion to Open Biology Data for AI. No Therapeutic Modality Is Named Biohub, the U.S. Department of Energy, NIH and partners announced $1.8 billion for open, AI-ready biological data. The release names no therapeutic modality, so GTC labels every cell and gene therapy implication as interpretation. AMT-130's Four-Year Primary Endpoint Missed Significance. The Huntington's BLA Rests on Three-Year Data 48-MONTH P=0.144 BLA ON 36 MONTHS September 30, 2026 · Clinical Data & Durability AMT-130's Four-Year Primary Endpoint Missed Significance. The Huntington's BLA Rests on Three-Year Data At 48 months, AMT-130's pre-specified primary endpoint, cUHDRS, showed 44% slowing and did not reach significance (p=0.144); TFC showed 61%. The BLA filed on September 2 rests on the 36-month analysis. What People in Australia Said Could Influence Funding Decisions on High-Cost Gene Therapies VALUE COUNTS BEYOND PRICE September 21, 2026 · Market Access & Value What People in Australia Said Could Influence Funding Decisions on High-Cost Gene Therapies A qualitative study asked 87 stakeholders recruited in Australia what value means when gene-therapy funding decisions must weigh patient and disease factors, access, benefits and harms, costs and uncertainty. Sanfilippo A Has Its First Gene Therapy. The Comparator Was an Untreated Historical Cohort FIRST FOR MPS IIIA HISTORICAL CONTROL September 18, 2026 · Regulatory Approvals Sanfilippo A Has Its First Gene Therapy. The Comparator Was an Untreated Historical Cohort The FDA approved Fayuvi for MPS IIIA, the first treatment for Sanfilippo syndrome type A. The efficacy study was open-label and single-arm, read against an untreated historical control cohort. A Gene Therapy That Ignores Which Gene Is Broken Is Now Under FDA Review GENE-AGNOSTIC IN FDA REVIEW September 17, 2026 · Regulatory Submissions A Gene Therapy That Ignores Which Gene Is Broken Is Now Under FDA Review The FDA has accepted Nanoscope Therapeutics' application to approve MOGENRY, a light-sensing (optogenetic) gene therapy for retinitis pigmentosa, and started its review. If approved, it would be the first treatment for the disease that works regardless of which gene is mutated. Encoded's $275M Dravet Round Pays for the Pivotal Trial and Its Own Manufacturing at Once $275M TRIAL + SCALE-UP September 11, 2026 · Financing & Clinical Development Encoded's $275M Dravet Round Pays for the Pivotal Trial and Its Own Manufacturing at Once Encoded Therapeutics closed a $275M Series F for ETX101, its Dravet syndrome gene therapy. It will support the pivotal study and commercial scale-up of in-house GMP manufacturing. Elicera's CAR-T Escalation Never Found a Dose Limit. The Highest Dose Goes to Phase IIa ZERO DLTs HIGHEST DOSE September 10, 2026 · Clinical Development Elicera's CAR-T Escalation Never Found a Dose Limit. The Highest Dose Goes to Phase IIa Elicera's CARMA Phase I finished with no dose-limiting toxicities reported, so the safety board picked the highest dose tested for the Phase IIa expansion. A Base Editor That Skips the Mutation Just Worked Across Four Different Genotypes SKIPS THE MUTATION 4 GENOTYPES September 8, 2026 · Gene Editing & Clinical Data A Base Editor That Skips the Mutation Just Worked Across Four Different Genotypes CorrectSequence treated four patients from Nigeria, Laos, Malaysia and Pakistan, carrying four different genotypes. The editor never touches the causative mutation — it switches a second gene back on, which is why one strategy can span all four. uniQure Filed on September 2 With Evidence the FDA Declined in March and Accepted in June 107 DAYS FDA REVERSAL September 7, 2026 · Regulatory Submissions uniQure Filed on September 2 With Evidence the FDA Declined in March and Accepted in June On 2 September uniQure filed a Huntington’s BLA on a three-year Phase I/II analysis against an Enroll-HD external control. On 2 March the FDA said that evidence was not sufficient and recommended a sham surgery-controlled study. On 17 June it said the same analysis would serve as the primary basis of a BLA. Three Deaths Paused Novartis Autoimmune CAR-T. BMS Paused Too, and Both Used Rapid Manufacturing TWO CAR-T HALTS ONE PLATFORM September 2, 2026 · Safety & Manufacturing Three Deaths Paused Novartis' Autoimmune CAR-T. BMS Paused Too, and Both Used Rapid Manufacturing Novartis halted eight autoimmune and neuroscience trials of its CD19 CAR-T after three deaths from serious IEC-HS. Days later BMS paused its own. Same target, different companies, and both built on a rapid manufacturing platform. The Liver Replaces Its Own Cells — This CRISPR Edit's Effect Held Flat for a Year CRISPR EDIT HELD 1 YEAR August 31, 2026 · Clinical Data & Durability The Liver Replaces Its Own Cells — This CRISPR Edit's Effect Held Flat for a Year A year after one CRISPR infusion, ANGPTL3 and lipid levels were still low and flat — in a liver that replaces nearly 20% of its cells every year. An investigator says the FDA has asked for 15 years of follow-up. A Fix for One REGENXBIO Gene Therapy Just Triggered a Hold on Another 5 OF 48 CLINICAL HOLD August 25, 2026 · Patient Safety & Regulatory A Fix for One REGENXBIO Gene Therapy Just Triggered a Hold on Another REGENXBIO's RGX-121 was placed on a new FDA clinical hold after asymptomatic spine findings in 5 of 48 trial participants — caught only by monitoring built for a different drug. FDA Approved a $2.7M Gene Therapy for GSDIa — 1 in 10 Patients Had Anaphylaxis in Trials FDA APPROVED ANAPHYLAXIS August 21, 2026 · Regulatory Approvals FDA Approved a $2.7M Gene Therapy for GSDIa — 1 in 10 Patients Had Anaphylaxis in Trials GENGLYCOS just became Ultragenyx's first approved gene therapy. Its own trial data lists seven serious adverse events, including a 10% anaphylaxis rate. No Law Required RiboX to Disclose This Death — the FDA Relied on the Data Anyway 3 TRIAL DEATHS NONE ANNOUNCED August 19, 2026 · Patient Safety & Regulatory No Law Required RiboX to Disclose This Death — the FDA Relied on the Data Anyway Three patient deaths in China's trials surfaced within weeks. Days before the third, the FDA leaned on the same trial-data class for an approval. Bankrupt Sangamo's Pipeline Just Sold for $163.55M BANKRUPTCY ASSETS SOLD August 18, 2026 · M&A & Bankruptcy Bankrupt Sangamo's Pipeline Just Sold for $163.55M Sangamo filed for Chapter 11 in June 2026. Six weeks later, PTC and Eli Lilly bought its gene therapy assets for $163.55 million.

AAV to AI, Edition 02

Three signals. Four published stories.

Read the free PDF, 40 pages of decision context behind this week's key CGT developments.

Download Edition 02

Or join the GTC Expert Network for access to future AAV to AI editions as the library grows. Members access the library in TopicBoard.